|
XI'AN, China, April 28, 2026 /PRNewswire/ -- Natural Field announced that the latest research and development breakthrough of the NFTriSolve® co-loading liposome technology has been achieved. Through a comparison of different formulations and processes in a zebrafish experiment, the research results show that the NFTriSolve® four-component formula demonstrates significant advantages over traditional formulations, especially in terms of brightening skin tone, moisturizing, and anti-aging effects.
In this experiment, the NFTriSolve® four-component formula (composed of ergothioneine, N-acetylneuraminate, coenzyme Q10 co-loaded liposome, and NMN co-loaded liposome) outperformed traditional single and three-component formulas in multiple dimensions, validating its powerful potential in enhancing skin health and delaying aging. Specific research data is as follows:
Formula Comparison Results:
Compared to the single-component and three-component formulas, the NFTriSolve® four-component formula showed superior performance in brightening skin tone, moisturizing, and anti-aging effects, demonstrating stronger multidimensional effects and higher bioavailability.
Process Comparison Results:
The NMN co-loaded liposome demonstrated better efficacy in brightening skin tone, moisturizing, and anti-aging compared to the use of NMN alone. The coenzyme Q10 co-loaded liposome significantly outperformed the use of coenzyme Q10 alone in various anti-aging indicators, showcasing the tremendous advantages of the liposome delivery system in enhancing ingredient efficacy.
This research result further strengthens NFTriSolve® technology's leadership position in the anti-aging field and provides solid technical support for the development of future anti-aging products and functional foods.
Natural Field to Showcase Innovative Formulas and Leading Research at Vitafoods Europe 2026.
Natural Field will showcase this innovative formula and other leading scientific achievements at the upcoming Vitafoods Europe 2026 exhibition. The event will provide the company with an opportunity to engage deeply with global industry experts and potential partners, exploring the market applications of next-generation anti-aging technologies and products. The company will continue to advance its technical research in the anti-aging field, offering more efficient, safe, and innovative functional formulations to global consumers, while driving the sustainable development of the health industry.
XI'AN, China, April 28, 2026 /PRNewswire/ -- Natural Field announced that the latest research and development breakthrough of the NFTriSolve® co-loading liposome technology has been achieved. Through a comparison of different formulations and processes in a zebrafish experiment, the research results show that the NFTriSolve® four-component formula demonstrates significant advantages over traditional formulations, especially in terms of brightening skin tone, moisturizing, and anti-aging effects.
In this experiment, the NFTriSolve® four-component formula (composed of ergothioneine, N-acetylneuraminate, coenzyme Q10 co-loaded liposome, and NMN co-loaded liposome) outperformed traditional single and three-component formulas in multiple dimensions, validating its powerful potential in enhancing skin health and delaying aging. Specific research data is as follows:
Formula Comparison Results:
Compared to the single-component and three-component formulas, the NFTriSolve® four-component formula showed superior performance in brightening skin tone, moisturizing, and anti-aging effects, demonstrating stronger multidimensional effects and higher bioavailability.
Process Comparison Results:
The NMN co-loaded liposome demonstrated better efficacy in brightening skin tone, moisturizing, and anti-aging compared to the use of NMN alone. The coenzyme Q10 co-loaded liposome significantly outperformed the use of coenzyme Q10 alone in various anti-aging indicators, showcasing the tremendous advantages of the liposome delivery system in enhancing ingredient efficacy.
This research result further strengthens NFTriSolve® technology's leadership position in the anti-aging field and provides solid technical support for the development of future anti-aging products and functional foods.
Natural Field to Showcase Innovative Formulas and Leading Research at Vitafoods Europe 2026.
Natural Field will showcase this innovative formula and other leading scientific achievements at the upcoming Vitafoods Europe 2026 exhibition. The event will provide the company with an opportunity to engage deeply with global industry experts and potential partners, exploring the market applications of next-generation anti-aging technologies and products. The company will continue to advance its technical research in the anti-aging field, offering more efficient, safe, and innovative functional formulations to global consumers, while driving the sustainable development of the health industry.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Natural Field Releases Research Findings on NFTriSolve® Co-Loading Liposome Formula
SAN DIEGO and NEWARK, Del., April 28, 2026 /PRNewswire/ -- Recently, ACROBiosystems was honored as a "Protein Supplier to Watch in Cancer Research in 2026" at the CiteAb Awards.
CiteAb accelerates scientific research by providing a search engine and data services, and its awards leverage high-quality citation data from publications to impartially recognize excellence in the reagent industry.
The award is based on analysis of the CiteAb protein database, which tracks over 300 suppliers. ACROBiosystems was recognized for achieving the second-highest year-over-year growth in protein citations from cancer-related publications, meeting the required citation threshold.
"We are pleased to recognise ACROBiosystems as Highly Commended in the Protein Supplier to Watch in Cancer Research Award." — Official citation from CiteAb Awards.
At the American Association for Cancer Research (AACR) event, ACROBiosystems' Dr. Yu Sun, VP of Product Development received the award and stated, "I am truly delighted that our proteins have earned top citations from scientists - this represents recognition and trust from the industry."
"ACROBiosystems' portfolio extends beyond proteins to include antibodies, kits, and services. These are applied not only to oncology but also to autoimmune diseases, cardiovascular diseases, infectious diseases, neurology, and other therapeutic areas. They support R&D and production processes including drug screening/optimization, preclinical research, clinical trials, CMC development, and diagnostic reagent development."
"ACROBiosystems upholds the core brand value of 'Reliable Quality, Integrated Innovation, Considerate Service', and is committed to providing innovative products and solutions to overcome challenges throughout the entire biopharmaceutical process, from R&D and production to clinical application."
ACROBiosystems Group's strategic commitment to quality is upheld through a stringent quality management system. The Group obtained ISO 9001 certification in 2016, established a GMP system in 2021, and achieved dual ISO 9001 and GMP certification at its Suzhou production site in 2024. Its specialized quality team monitors global regulations and industry trends, enabling agile adaptation of management systems to diverse product profiles, customer applications, and evolving compliance requirements—ensuring development and production align with both client specifications and regulatory standards.
The company's "Considerate Service" is reflected in several key dimensions: expedited logistics that ensure industry-leading delivery; 24-hour technical support for immediate issue resolution; a comprehensive resource repository providing insights and protocols; and personalized client attention through dedicated service teams.
Similarly, "Integrated Innovation" is demonstrated through multiple facets: alignment with emerging therapeutic modalities, focus on pivotal disease areas, advancement of technology platforms enhanced by AI, and active collaboration within global innovation ecosystems.
About ACROBiosystems Group
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. The company spans across the globe and maintains offices, R&D centers, and production bases in more than 15 different cities within the United States, Switzerland, the United Kingdom and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world's top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.
Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and their clinical applications, and contributes to global health.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
ACROBiosystems Wins CiteAb Award, Gaining Worldwide Recognition
ACROBiosystems Wins CiteAb Award, Gaining Worldwide Recognition
